None listed
Conditions
Brief summary
This study is examining brain tumour blood flow and drug uptake in patients with brain tumours originating from breast cancer. Who is it for? You may be eligible for this study if you are aged 18 or over and have a history of breast cancer, with radiologically diagnosed metastatic brain disease. Study details All participants will have an intravenous infusion containing a chemical tracer used in a PET scan. On the day of administration, plus an additional one or two occasions in the following week, participants will have a PET-MR scan. The study aims to use imaging to examine the uptake of the chemical tracer in brain metastases originating from breast cancer. It will provide new information about how treatment could be affected by unique blood flow patterns in the brain.
Interventions
Breast cancer patients with radiologically confirmed brain metastases will be administered ONCE with up to 10mg of a pertuzumab-[89]Zr PET tracer, and 50mg of unconjugated pertuzumab (loading dose to minimise nonspecific uptake of the tracer) by intravenous infusion. A Registered Nurse will administer the pertuzumab under supervision of a Medical Officer. On the day of administration, and on 1-2 occasions during the following week, brain tumour uptake of the tracer will be quantified by PET-MR i
Breast cancer patients with radiologically confirmed brain metastases will be administered ONCE with up to 10mg of a pertuzumab-[89]Zr PET tracer, and 50mg of unconjugated pertuzumab (loading dose to minimise nonspecific uptake of the tracer) by intravenous infusion. A Registered Nurse will administer the pertuzumab under supervision of a Medical Officer. On the day of administration, and on 1-2 occasions during the following week, brain tumour uptake of the tracer will be quantified by PET-MR imaging. Imaging will be performed by an accredited Nuclear Medicine Technologist, with supervision by a Medical Officer.
Sponsors
The University of Queensland
Study design
Allocation
Non-randomised trial
Primary purpose
Diagnosis
Eligibility
Sex/Gender
All
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
- Adults at least 18 years of age - History of breast cancer with HER2 status confirmed according to standard diagnostic criteria - One or more new or recurrent metastatic brain tumour(s) diagnosed radiologically - Willing and able to tolerate multiple rounds of imaging - Willing and able to provide informed consent & attend appointments - Adequate kidney function (eGFR>30) for Gad-DTPA excretion
Exclusion criteria
- History of intolerance or hypersensitivity to pertuzumab - Leptomeningeal disease - Prior surgical resection of lesions in the same hemisphere within 4 weeks - Prior radiation treatment of proximal lesions - History of congestive heart failure or left ventricular dysfunction (LVEF <50%) - Active infection - Claustrophobia - Pregnant or breastfeeding now or in the near future
Outcome results
None listed